Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis

Teiji Kuzuya, Kaoru Tsuchiya, Keisuke Tanaka, Yuichiro Suzuki, Takahide Hoshioka, Shinji Tamaki, Tomoji Kato, Yutaka Yasui, Takahiro Hosokawa, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Yasuhiro Asahina, Namiki Izumi

Research output: Contribution to journalArticle

Abstract

We investigated efficacy of sorafenib therapy for advanced hepatocellular carcinoma (HCC) with Vp3/4 portal vein tumor thrombosis. According to modified RECIST, the therapeutic responses in Vp0/2 group (n=30) were 8 PR, 14 SD and 8 PD cases, and while those in Vp3/4 group (n=11) were 5 PR, 2 SD and 4 PD cases. The response rates and cumulative progression rates were not significantly different between two groups. The cumulative survival rates in Vp3/4 group were significantly lower than those in Vp0/2 group. The deteriorations of Child-Pugh scores in Vp3/4 group were significantly higher than those in Vp0/2 group. The possibility of the deterioration of liver function should be kept in mind during sorafenib therapy for advanced HCC with Vp3/4.

Original languageEnglish
Pages (from-to)325-326
Number of pages2
JournalActa Hepatologica Japonica
Volume52
Issue number5
DOIs
Publication statusPublished - 2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hepatology

Fingerprint Dive into the research topics of 'Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis'. Together they form a unique fingerprint.

  • Cite this

    Kuzuya, T., Tsuchiya, K., Tanaka, K., Suzuki, Y., Hoshioka, T., Tamaki, S., Kato, T., Yasui, Y., Hosokawa, T., Ueda, K., Nakanishi, H., Itakura, J., Takahashi, Y., Kurosaki, M., Asahina, Y., & Izumi, N. (2011). Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis. Acta Hepatologica Japonica, 52(5), 325-326. https://doi.org/10.2957/kanzo.52.325